As a key regulator in cancer, eIF3a is expressed at high levels in multiple cancers and is relevant to the sensitivity of DNA damage-induced therapy, such as platinum agents (Zhang Y. et al., 2015) and ionizing radiation (Tumia et al., 2020). Here, EIF3A is linked to cancer.